<DOC>
	<DOC>NCT01835548</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age.</brief_summary>
	<brief_title>NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory classroom study.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Currently being treated for ADHD Other psychiatric diagnoses Significant cognitive impairment Chronic medical illnesses Structural cardiac defects Significant abnormal lab tests Taking disallowed medications Positive drug test</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>